Rhenman & Partners Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6M	Buy	+119,300	New	+$8.71M	1%	47

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rhenman & Partners Asset Management's SYRE Position: Q2 2026 in Review

Rhenman & Partners Asset Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 119,300 shares worth $10.6M. The stake represents 1% of the portfolio and ranks #47 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Rhenman & Partners Asset Management held 119,300 shares of Spyre Therapeutics worth $10.6M as of Q2 2026.
Spyre Therapeutics was a new Rhenman & Partners Asset Management position in Q2 2026.
Spyre Therapeutics made up 1% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #47 holding.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.